Short-term Tezepelumab effectiveness in patients with severe asthma: a multicenter study

Area of Science:

• Pulmonology
• Immunology
• Pharmacology

Background:

• Severe asthma management remains challenging, often necessitating advanced therapies.
• Monoclonal antibodies have transformed severe asthma care by reducing exacerbations and improving quality of life.
• Tezepelumab, targeting thymic stromal lymphopoietin (TSLP), is a novel therapeutic candidate.

Purpose of the Study:

• To evaluate the short-term efficacy and safety of Tezepelumab in patients with severe asthma.
• To assess the impact of Tezepelumab on asthma control, exacerbations, and oral corticosteroid (OCS) use.
• To explore potential correlations between treatment outcomes and inflammatory biomarkers or allergic sensitization.

Main Methods:

• An observational, prospective, multicenter study involving 20 severe asthma patients.
• Patients received Tezepelumab 210 mg every 4 weeks for uncontrolled asthma despite maximal inhalation therapy.
• Data collection occurred at baseline (T0) and three months post-initiation (T3).

Main Results:

• Significant improvements in asthma symptoms and quality of life were observed after three months.
• A consistent reduction in exacerbations and OCS use was reported.
• Lung function improved in patients with lower allergic sensitization; no significant differences were noted based on inflammatory biomarkers. Mild adverse events were comparable to clinical trials, with no serious adverse events.

Conclusions:

• Tezepelumab demonstrated short-term efficacy in enhancing asthma control and patient quality of life.
• The treatment exhibited a favorable safety profile in this cohort.
• Larger, longer-term studies are warranted to confirm findings and identify response predictors.